Skip to main content

Ocugen expects $53.5M from stock sale amid efforts to bring Covaxin to the U.S.

Ocugen is continuing its efforts to bring a Covid-19 vaccine developed in India to the United States.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.